Scale to stratify magnitude of clinical benefit of anticancer medicines

Related posts:

1. Ibrutinib and chemotherapy reduce risk of death in patients with CLL or SLL Because of the significant benefit found in combining the targeted drug ibrutinib with standard chemotherapy for relapsed chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), an interim analysis has closed the international HELIOS phase III clinical trial. ...
2. Blood pressure medications can lead to increased risk of stroke The importance of preventing hypertension is reinforced by a study showing anti-hypertension medicines can increase stroke risk by 248 percent, according to new research. ...
3. Altered pain processing in patients with cognitive impairment People with dementia and other forms of cognitive impairment (CI) have altered responses to pain, with many conditions associated with increased pain sensitivity, concludes a new research review. ...
4. Hypothermia occurs during surgery in around half of patients A study shows that hypothermia occurs in around half of patients undergoing surgery, despite national guidelines for its prevention. ...
5. Targeted drug can ‘diminish the suffering’ of myelofibrosis Use of the targeted agent pacritinib significantly reduced the symptoms and burden of advanced myelofibrosis in patients, says a researcher who co-led PERSIST-1, the worldwide phase 3 clinical trial that tested the therapy. Specifically, pacritinib substantially reduced severe enlargement of the spleen, a typical feature of advanced myelofibrosis, in more than 20 percent of patients and alleviated debilitating side effects in more than 46 percent. ...